Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
Sponsored by Indiana University
About this study
This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.
Where this study is enrolling (7)
- I'm interested
Hoag Memorial Hospital
Newport Beach, California
- I'm interested
Emory University
Atlanta, Georgia
- I'm interested
Northwestern University
Chicago, Illinois
- I'm interested
Maine Health Research Institute
Portland, Maine
- I'm interested
Harvard Medical School
Boston, Massachusetts
Show all 7 locations
- I'm interested
Henry Ford Hospital
Detroit, Michigan
- I'm interested
Mount Sinai
New York, New York
Who can participate
Inclusion criteria
- ✓Adults ≥18 years of age
- ✓Clinical diagnosis of T1D
- ✓GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
- ✓Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
- ✓Willing and able to provide informed consent
Exclusion criteria
- ✕No exclusion criteria other than those not meeting inclusion criteria above
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.